(Reuters) - Amgen Inc said its cancer drug significantly improved the length of time that patients lived with a type of blood cancer without the disease worsening. Amgen's share rose 4.3 percent to $130.96 in premarket trading on Monday after the company released the interim data from a late-stage study. The trial was testing the drug, Kyprolis, in combination with two other treatments, against those treatments alone in previously-treated patients with relapsed multiple myeloma. (Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)
via Health News Headlines - Yahoo News http://ift.tt/1tNdr6R
No comments:
Post a Comment